Here's an interesting article related to the vaccine. Professor Sir Andrew Pollard, who is the director of the Oxford Vaccine Group, came out saying that the vaccine will not prevent virus variants from spreading. What's particularly interesting about this is the fact that the Oxford Vaccine Group owns the AstraZeneca brand. So, why would the head of this group effectively tell people that the vaccine is ineffective and possibly counterproductive?
The answer to this may be found in the fact that AstraZeneca is a money losing venture. The Oxford Vaccine Group loses nothing by throwing a spanner into the vaccine rollout and the associated push for vaccine passports. On the contrary, they save themselves money, and protect themselves against future blowbacks in the process.
Andrew Pollard's statement may also be a personal attack on Albert Bourla, the CEO of Pfeizer.
AstraZeneca got a lot of bad press from the very start, and it's not impossible that Albert Bourla had a thing or two to do with that. Even the suspicion of foul play may have encouraged Andrew Pollard to get back at him. The move may also have been motivated by envy. Neither of the two men are of the upright and honest type, so intrigues of this kind cannot be ruled out.
Here again, we see signs of disarray within the state and its affiliated corporations. As always, evil leads to chaos. It's becoming increasingly clear that the vaccine is a failed experiment. The rats are leaving the ship, and the ones with the least to lose and most to gain are leading the pack.
Smallpox vaccine |
By Photo Credit: James Gathany Content Providers(s): CDC - This media comes from the Centers for Disease Control and Prevention's Public Health Image Library (PHIL), with identification number #2674. Note: Not all PHIL images are public domain; be sure to check copyright status and credit authors and content providers. , Public Domain, Link
No comments:
Post a Comment